• 1 January 1977
    • journal article
    • research article
    • Vol. 55  (2) , 69-73
Abstract
Sufficient quantities of human leukocyte interferon have become available for small-scale clinical studies during the past years. The present status of interferon treatment of respiratory infections, herpes keratitis, hepatitis B, osteogenic sarcoma and some other tumors is surveyed. Pharmacokinetic and toxicological data are summarized. The first clinical experiments with human fibroblast interferon have been started. Prospects for mass production of human interferons for clinical use are discussed briefly.